Brief: Pixium Vision announces updates on its epi-retinal Iris II bionic vision system
27/09/2017 06:01
Sept 27 (Reuters) - PIXIUM VISION SA PIX.PA
* PIXIUM VISION ANNOUNCES UPDATES ON ITS EPI-RETINAL IRISII
BIONIC VISION SYSTEM
* 6-MONTH FOLLOW-UP DEMONSTRATES THAT IRIS()II IMPROVES
VISUAL PERFORMANCE AND HAS A FAVORABLE SAFETY PROFILE
* A SHORTER THAN EXPECTED LIFESPAN OF DEVICE WAS NOTICED IN
THIS SET OF PATIENTS
* NONETHELESS DECIDED TO TEMPORARILY HALT NEW IMPLANTATIONS
* SHORTER THAN EXPECTED LIFESPAN OF DEVICE PRESENTS NO RISK
TO IMPLANTED PATIENTS
* FIRST COMMERCIAL IRIS()II IMPLANT CARRIED OUT IN SPAIN
WAS SUCCESSFULLY ACTIVATED RECENTLY
Source text for Eikon: urn:newsml:reuters.com:*:nBw7Kh6rZa
Further company coverage: PIX.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Pixium Vision SA
See all newsBrief: Pixium Vision SA Says Paris Commercial Court Postponed Decision On Takeover Offer Filed On Nov 20, 2023
Brief: Pixium Vision: opening of judicial liquidation proceedings has been postponed to later date
Brief: Pixium Vision Announces Decision About Adoption Of Sale Plan, Opening Of Judicial Liquidation Proceedings Planned For Jan 16, 2024
Brief: Pixium Vision SA Announces Conversion Of Safeguard Proceedings Into Receivership
Brief: Pixium Vision Announces Tender Process For Purpose Of Finding Buyers To Acquire Company's Business Will Be Published Tomorrow